Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
Clinical trial NCT03802240 · COMPLETED
Trial details
- NCT number
- NCT03802240
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-11
- Primary completion
- 2021-07-31
- Enrollment
- 492
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.